Edition:
India

Akebia Therapeutics Inc (AKBA.OQ)

AKBA.OQ on NASDAQ Stock Exchange Global Market

10.29USD
20 Jul 2018
Change (% chg)

$-0.22 (-2.09%)
Prev Close
$10.51
Open
$10.51
Day's High
$10.66
Day's Low
$10.14
Volume
91,419
Avg. Vol
185,102
52-wk High
$20.25
52-wk Low
$7.90

Chart for

About

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $894.46
Shares Outstanding(Mil.): 47.15
Dividend: --
Yield (%): --

Financials

Ex-Akebia employee jailed for night as insider trading trial starts

BOSTON A former Akebia Therapeutics Inc employee accused of engaging in an insider trading scheme must spend a night in jail after he violated a U.S. judge's order and spoke to a witness at the start of his trial on Tuesday.

27 Jun 2018

CORRECTED-Ex-Akebia employee jailed for night as insider trading trial starts

BOSTON, June 26 A former Akebia Therapeutics Inc employee accused of engaging in an insider trading scheme must spend a night in jail after he violated a U.S. judge's order and spoke to a witness at the start of his trial on Tuesday.

27 Jun 2018

BRIEF-Akebia Therapeutics Reports Q1 Loss Per Share $0.48

* AKEBIA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

10 May 2018

BRIEF-Akebia Therapeutics Announces Proposed Public Offering Of Common Stock

* AKEBIA THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

23 Mar 2018

BRIEF-Akebia Therapeutics Inc Files For Potential Mixed Shelf Offering Amount Not Disclosed - SEC Filing

* AKEBIA THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; AMOUNT NOT DISCLOSED - SEC FILING Source text (http://bit.ly/2tG5aJJ) Further company coverage: (Reuters.Brief@thomsonreuters.com)

13 Mar 2018

BRIEF-Akebia Therapeutics Announces Q4 Earnings Per Share $0.25

* AKEBIA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

13 Mar 2018

BRIEF-Akebia Therapeutics Gives Update On Vadadustat Development Program

* AKEBIA THERAPEUTICS PROVIDES UPDATE ON VADADUSTAT DEVELOPMENT PROGRAM

12 Feb 2018

Competitors

  Price Chg
Amgen, Inc. (AMGN.OQ) $190.49 -1.27
Johnson & Johnson (JNJ.N) $125.85 -0.09
Roche Holding Ltd. (ROG.S) CHF234.00 +2.05
Roche Holding Ltd. (RO.S) CHF238.60 +2.80
FibroGen Inc (FGEN.OQ) $65.05 +0.65
AstraZeneca plc (AZN.L) 5,589.00 -20.00
Astellas Pharma Inc (4503.T) ¥1,808 +0.50
GlaxoSmithKline plc (GSK.L) 1,549.80 -8.20
Bayer AG (BAYGn.DE) €92.05 -0.30
Bayer AG (BAYE.F) -- --

Earnings vs. Estimates